Clinical trial
A Multi-center, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone for the Prevention of NSAID-induced Gastroduodenal Injury in Patients With Osteoarthritis and/or Rheumatoid Arthritis Patients
NCT00597818 is registered in ClinicalTrials.gov with Sucampo Pharma Americas, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone for the Prevention of NSAID-induced Gastroduodenal Injury in Patients With Osteoarthritis and/or Rheumatoid Arthritis Patients
- Lead sponsor
- Sucampo Pharma Americas, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2007
- Completion date
- May 31, 2009
- Enrollment
- 121 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
nsaid-induced gastroduodenal injury, osteoarthritis, rheumatoid arthritis, ulcers